News
-
Janssen Biotech, Inc. Announces Collaborative Development And Worldwide License Agreement For Investigational Anti-Cancer Drug, PCI-32765
12/14/2011
Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced recently that it has executed an agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765.
-
MIT Research: Proteins Linked To Longevity May Be Involved In Mood Control
12/12/2011
Over the past decade, MIT biologist Leonard Guarente and others have shown that very-low-calorie diets provoke a comprehensive physiological response that promotes survival, all orchestrated by a set of proteins called sirtuins. By Anne Trafton, MIT
-
Novartis Gains European Commission Approval For Rasitrio, A Rasilez-Based Triple Combination Pill To Treat High Blood Pressure
11/29/2011
Novartis announced recently that Rasitrio, the first triple combination of aliskiren, amlodipine and hydrochlorothiazide (HCT) in a single pill,1 has received approval from the European Commission (EC) for the treatment of high blood pressure.
-
Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
11/8/2011
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced positive results from a study in patients with type 1 diabetes that receive their insulin therapy via pumps.
-
Roche Starts Early Stage Clinical Trial In Down Syndrome
9/12/2011
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of its first Phase 1 clinical trial to investigate the safety and tolerability of a molecule designed to address the cognitive and behavioral deficits associated with Down syndrome.
-
Top-Line Results From Pivotal Trial Of Dermagraft For Venous Leg Ulcers
8/25/2011
Shire plc, the global specialty biopharmaceutical company, recently announced that Advanced BioHealing (ABH), its regenerative medicine business, has concluded its phase three pivotal trial of Dermagraft in subjects with venous leg ulcers.
-
Amarantus BioSciences And Generex Biotechnology Collaborate On Cell Therapy For Late Stage Diabetes
8/5/2011
Amarantus BioSciences, a biotechnology company developing a first-in-class anti-apoptosis therapeutic protein known as MANF, and Generex Biotechnology, a biotechnology company developing a buccal insulin spray technology known as Generex Oral-lyn, currently in a Phase III trial, recently are making public the details of their intended third joint diabetes research collaboration.
-
Isis Initiates Phase 1 Study Of ISIS-PTP1BRx To Treat Type 2 Diabetes
7/25/2011
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-PTP1BRx, an antisense drug for the treatment of type 2 diabetes targeting protein tyrosine phosphatase-1B, PTP-1B.
-
Penn Study Finds A Genetic Basis For Muscle Endurance In Animal Study
7/25/2011
Researchers at the Perelman School of Medicine at the University of Pennsylvania have identified a gene for endurance, or more precisely, a negative regulator of it.
-
inVentiv Health Completes PharmaNet Acquisition
7/15/2011
inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced it has completed the acquisition of PharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries.
This website uses cookies to ensure you get the best experience on our website. Learn more